Disease · MONDO_0005485
Comparisons in its trials14
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 14 of 14
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Pimavanserin 40 mg vs Placebo: deaths from any cause | 4 of 90 | 4 of 91 | 181 | NCT02035553 | Trial comparisons |
| Pimavanserin 40 mg vs Placebo: serious adverse events | 15 of 90 | 10 of 91 | 181 | NCT02035553 | Trial comparisons |
| Asenapine 2-10 mg Twice Daily (BID) vs Asenapine 5-10 mg BID: Number of Participants Who Discontinued Because of an Adverse Event | 12 of 61 | 9 of 61 | 122 | NCT00281320 | Trial comparisons |
| Asenapine 2-10 mg Twice Daily (BID) vs Asenapine 5-10 mg BID: Number of Participants Who Experienced an Adverse Event | 44 of 61 | 44 of 61 | 122 | NCT00281320 | Trial comparisons |
| Asenapine 2-10mg BID vs Asenapine 5-10mg BID: serious adverse events | 6 of 61 | 3 of 61 | 122 | NCT00281320 | Trial comparisons |
| GWP42003 1000 mg/Day vs Placebo: serious adverse events | 0 of 43 | 1 of 45 | 88 | NCT02006628 | Trial comparisons |
| Novel Lipid Formulation Cannabidiol vs Standard Formulation Cannabidiol: deaths from any cause | 0 of 14 | 0 of 14 | 28 | NCT05032807 | Trial comparisons |
| Novel Lipid Formulation Cannabidiol vs Standard Formulation Cannabidiol: serious adverse events | 0 of 14 | 0 of 14 | 28 | NCT05032807 | Trial comparisons |
| Olanzapine Group vs Clozapine Group: serious adverse events | 1 of 13 | 2 of 12 | 25 | NCT00001656 | Trial comparisons |
| Cannabidiol, Then Placebo vs Placebo, Then Cannabidiol: deaths from any cause | 0 of 8 | 0 of 10 | 18 | NCT02504151 | Trial comparisons |
| Cannabidiol, Then Placebo vs Placebo, Then Cannabidiol: serious adverse events | 2 of 8 | 0 of 10 | 18 | NCT02504151 | Trial comparisons |
| Meclofenamic Acid vs Pentosan Polysulfate Sodium: deaths from any cause | 0 of 2 | 0 of 6 | 8 | NCT02930005 | Trial comparisons |
| Meclofenamic Acid vs Pentosan Polysulfate Sodium: serious adverse events | 0 of 2 | 0 of 6 | 8 | NCT02930005 | Trial comparisons |
| Metyrosine vs Placebo: serious adverse events | 0 of 1 | 0 of 1 | 2 | NCT01127503 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005485/comparisons